Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate.

Annals of hematology - 1 Nov 2022

Ebisawa Kazutoshi, Masamoto Yosuke, Yagi Koichi, Kurokawa Mineo

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imatinib Mesylate
Share to Janus Kinase 2
Share to Mutation
Share to Polycythemia Vera

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 35932325
DOI: 10.1007/s00277-022-04940-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate.PMID 35932325Read ↗

[Essential thrombocythemia with JAK2 V617F mutation transformed into acute myeloid leukemia without JAK2 V617F mutation:case report and literature review].Semantic proximity Read ↗

A Clue in JAK2: Masked Polycythemia Vera.Semantic proximity Read ↗

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.Semantic proximity Read ↗

JAK2 mutations other than V617F: a novel mutation and mini review.Semantic proximity Read ↗

Clinical implications of the JAK2 V617F mutation in essential thrombocythemiaSemantic proximity Read ↗

JAK2 V617F: a single mutation in the myeloproliferative group of disorders.Semantic proximity Read ↗

JAK2V617F Exon-14 Mutation Driven Polycythemia Vera.Semantic proximity Read ↗

JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.Semantic proximity Read ↗

Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.Semantic proximity Read ↗

Intriguing outcome of JAK2V617F mutation seen in a patient with MYH9-related hereditary macrothrombocytopenia.Semantic proximity Read ↗

JAK2 V617F clonal disorders: fate or chance?Semantic proximity Read ↗

Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.